Interestingly, ovarian cancer patients with the PARP1 p.R591C mutation (c.1771C>T) showed de novo resistance to olaparib, suggesting that this is partly validated in clinics as a mechanism of resistance to PARP inhibitors. Here, PARP1 is linked to ovarian cancer.